Patients w/ chronic hepatitis B or C treated w/ antiretroviral therapy; co-infected w/ HIV-1 & HBV/HCV. Closely monitor patients co-infected w/ HIV & HBV who discontinued Biktarvy for at least several mth after stopping treatment. Patients w/ significant underlying liver disorders. Monitor patients w/ preexisting liver dysfunction including those w/ chronic active hepatitis. Consider interruption or discontinuation of treatment if liver disease worsens. Wt gain & increase of blood lipid & glucose levels may occur. Mitochondrial dysfunction following exposure in utero
. Immune reactivation syndrome. Closely observe patients for opportunistic infections. Osteonecrosis. Nephrotoxicity. Concomitant use w/ Mg- or Al-containing antacids or Fe supplements. Not recommended to co-administer w/ atazanavir, boceprevir, carbamazepine, ciclosporin (IV or oral), oxcarbazepine, phenobarb, phenytoin, rifabutin, rifapentine or sucralfate, & other antiretrovirals. May affect ability to drive or operate machinery. Pregnancy & lactation.